An open trial evaluation of the benzodiazepine (information and reduction) digital health program (BDZ digital health) for people using benzodiazepines.

Not Applicable

Suspended

• Conditions: Benzodiazepine dependency; Mental Health - Depression; Depression; Mental Health - Anxiety; Anxiety; Mental Health - Addiction

• Registration Number: ACTRN12622000864729
• Lead Sponsor: Federation University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-17
• Last Update Posted: 29 July 2024

Recruitment & Eligibility

• Status: Suspended
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

Participants must be 18 years or older, currently using benzodiazepines, have access to the internet, provide consent, and be able to register online using an email address.

Exclusion Criteria

Participants must not be residing overseas, do not have a current untreated and severe (psychotic) illness, nor will they be using the ‘cold turkey’ method to reduce their benzodiazepine intake during the study (i.e., complete withdrawal from their benzodiazepines).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Benzodiazepine dependency will be measured by the Benzodiazepine Dependence Questionnaire.[ Pre-intervention (Week 0), post-intervention (Week 6), & 3 month follow-up (Week 18, primary endpoint) assessment.];Anxiety will be measured by the Generalised Anxiety Disorder-7 survey.[ Pre-intervention (Week 0), during intervention (Week 3), post intervention (Week 6, primary endpoint), and 3 month follow-up (Week 18).];Self-reported benzodiazepine medication use via online questions (Type & Dose)[ Pre-intervention (Week 0), post intervention (Week 6), and 3 month follow-up (Week 18).]